Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space.

(July 8, 2026 ) by Tristan Manalac

Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space.

Kalohexis, a recently spunout obesity-focused drugmaker, has filed for an initial public offering.

The Illinois startup has submitted its confidential registration statement with the SEC, according to a news release on Tuesday, keeping much of its offering’s details under wraps. Kalohexis hasn’t yet determined how many shares it will put up for sale, the proceeds it expects to raise or when the fundraise will close.

With the prospectus inaccessible, it remains unclear what exactly Kalohexis plans to do with its IPO haul.